A two ‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma.

A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma. Oncol Rep. 2018 Nov 02;: Authors: Guo J, Wang Z, Miao Y, Shen Y, Li M, Gong L, Wang H, He Y, Gao H, Liu Q, Li C, Zhang Y Abstract Clinical non‑functioning pituitary adenoma (NFPA) accounts for >30% of all pituitary adenomas, and the recurrence rate is notably high. The ability to predict tumour recurrence during initial surgery will aid in determining if adjunctive therapy is required to reduce recurrence. With the aim of developing a circular RNA (circRNA) signature to improve prognosis prediction in NFPA, the present study examined the circRNA expression profiles in 73 patients with NFPA from Beijing Tiantan Hospital using high‑throughput RNA chip technology. The dataset was randomly separated into a training group and a test group using an R program. In the training group (n=37), a Cox proportional hazards regression model was used to analyse the genes associated with the recurrence and progression‑free survival (PFS) of patients with NFPA. Meanwhile, a random survival forest algorithm, Kaplan‑Meier and receiver operating characteristic curve (ROC) analyses were used to determine the multi‑circRNA signature with the largest area under the ROC curve (AUROC) and verify its efficacy in the test group (n=36). In the training and test groups, the signatures of two circRNAs (hsa_circ_0000066 and hsa_circ_0069707) were spec...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research